Downloading...
Download

MNKD

Can MNKD be heading for a run up to $8.40'sMNKD has been consolidating for want seems to be forever, but since April of 2020 it's been catching a little bit of a pump which peaked sometime in March of this year. Since then it has created a symmetrical triangle. On its own a symmetrical triangle does not mean much, but if we look at other indicators like the weekly 200 MA, together with the RSI and the price action, we can try to put something together. What is showing us it that the price has been able to close above the 200 weekly MA for over 15 weeks in a roll. At the same time the 50 EMA on the weekly chart seems to be getting close to going over the 200 EMA and forming a GOLDEN CROSS. This still has not been confirmed, but as long as MNKD price can stay over $3.86, there is a good chance a run up to $8.90's is very possible.
NASDAQ:MNKDLong
by TheKingOfAces
MNKD Fibbin AgainMNKD is back at a frequent level of "traffic" this week. After doing a quick retracement we can see that the 618 area continues to act as a magnate a key pivot area. After bouncing off this last time, MNKD has continued higher on a decent multi-day move. Now, moving forward, a fundamental focus could be on what happens with its next potential commercial product, Tyvaso: MannKind’s collaboration partner, United Therapeutics (NASDAQ: UTHR), previously submitted an NDA to the FDA for its Tyvaso DPI product. This is a potential treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. In response to the strong Q2 performance, Michael Castagna, Chief Executive Officer of MannKind, said, “I am really proud of how our team has executed so far in 2021 supporting the growth of Afrezza and preparing for the potential commercial launch of Tyvaso DPI.” With this as the backdrop for a recent rally in MNKD stock, it could be a sign to have it as one of the penny stocks to watch heading into the second half of the month. Quote Source & Read More: Best Penny Stocks To Buy Right Now? 5 To Watch Before September
NASDAQ:MNKD
by PennyStocks101
MNKD 10x Potential, High R/RRapidly Hiring. They have a proprietary drug delivery platform known as the Technosphere. They deliver drugs through the lungs instead of injection or pills. Afrezza their FDA approved drug is finally starting to generate sales after being fda approved years ago. They are also working on several other products for 2020. Huge accumulation range and due to very aggressive short sellers flooding the market with over 40 million additional shares over the years. All of these short sales will eventually be pressured to rebuy rapidly driving up price. There are also warrants that were delayed and expire in July. With the healthcare sector and biotech improving at a rapid pace, an effective product, all the catalysts are there.
NASDAQ:MNKDLong
by TradeRepository
2
MNKD 1D ASCENDING TRIANGLE BREAKOUT LONGAscending Triangles are repeatable trading chart patterns. Ascending chart patterns will have a directional bias depending on the previous incoming trend. Each chart pattern will have defining trendlines of the support/resistance levels creating the pattern. What ever time frame you are trading this chart pattern, wait for a candle close outside of the trendline in the direction of the breakout candle. (Our time frame preference is the Daily chart). Add volume indicator - Volume is the amount of $ that went into a particular candle or in Forex the # of trades that took place. Add ATR indicator - Volatility is the amount of price movement that occurred. Use the ATR to measure the price movement. When you see descending Volume bars and descending ATR line (which indicates volatility) this shows a dis-interest in traders to invest in this pair creating consolidation which creates the chart pattern. Trade Management after there is a breakout candle close. 1 - Position size (compare volume bar to volume ma line). a - Breakout candle must be 100% of volume average for a full position size. b - If 75% of volume average then ½ position size. (To find 75% of Volume look at the charts volume settings – divide smaller # into larger # = 75%+) If not 75% then stand aside from the trade. 2 – If candle breaks out of a trendline, 15m before the close of the day prepare your buy/sell order. Enter two trades. 1st trade will have a SL & TP. It will close automatically when the 1st TP is hit. 2nd trade only has a SL and will be allowed to run. When 1st TP is hit move the SL to breakeven. Look at ATR and prepare SL at 1.5 of ATR. Prepare 1st trade TP at 1 of ATR. 3 - SL for both trades will be 1.5 x ATR. 4 - 1st trade TP will be 1 x ATR. 5 - No TP on 2nd trade – letting profit run and adjusting SL to follow price. 6 - When 1st TP hit – move 2nd trade SL to breakeven. 7 - Adjust the 2nd trade SL to follow price. *8 – After Breakout candle – if price closes back into chart pattern close trade don't wait for SL to be hit. *9 - When breakout candle is more than 1 ATR from breakout candle open. a - Enter 1st trade at candle close with ½ position size. b - Enter 2nd trade with a pending limit order that is 1 ATR of breakout candle open. c – Price should pullback to that pending limit order for 2nd trade. d – If Price returns back into chart pattern close trade before SL is hit.
NASDAQ:MNKDLong
by Tradingstrategyguides
OFTSA* -- MNKD NOV 17TH 5 SHORT PUT* -- Options for the Small Account Let's face it. This is a really tough market for small accounts. You can either wait to build up your account to something decent to actually be able to trade some of the broader (and more expensive) market offerings, dollar cost average in a few shares at a time at all time highs (that doesn't sound enticing, although that's what a lot of people do when they're first starting out), or you can do what you can afford, and that is likely to mean lower priced underlyings, a lot of which are low for a reason. However, there are various options strategies that will allow you to potentially make money on lower priced underlyings or use strategies such as Poor Man's Covered Calls on reasonably priced exchange-traded funds that don't expose you to single name risk (e.g., GDX, XOP, etc.). Granted, a bullish assumption play in MNKD isn't the best to start off this series with. MNKD has all sorts of warts, not the least of which is that 1/5 reverse split earlier this year. That being said, the background implied volatility is at a whopping 172%, making a short put/acquire/cover cycle trade ideal if it hangs in there around this price level for any period of time. Here, I'm looking to maximize the credit received at the door, and that is by going at-the-money: Probability of Profit: 60% Max Profit: .92 ($92)/contract** Break Even: 4.08/share Delta: 34.82 Theta: 1.53 The notion here is to run the option until expiry. If, at expiry, price is above the 5 strike, I keep the entire risk premium collected. If below, I am assigned shares at $5, but with a cost basis of $4.08. At that point, I will immediately sell short calls against the position, further reducing cost basis and will look to bail from the position via call away at the short call price. ** -- Friday's close mid price for the 5 short put was .92, which may require some adjustment on market open.
NASDAQ:MNKDLong
by NaughtyPines
4
Heavy short interest, proprietary technologyNow looks like a smart time to be investing in MNKD. Not only is Afrezza a better insulin than many available, not only does the technosphere eliminate a lot of potential unnecessary needles... the technosphere is the potential gold mine here. Imagine the FLU SHOT being a thing of the past... for the new, improved delivery system of a FLU INHALER. FDA can fast track drugs thru using technosphere... its already FDA approved. Many cultures in the world wont even USE a needle. Not to mention, HUGE SHORT INTEREST... once this sets fire, its gonna blaze...
NASDAQ:MNKDLong
by AndrewMills